Shelton Capital Management Lowered Jpmorgan Chase & Co (JPM) Position By $3.94 Million; 11 Bullish Analysts Covering Cytokinetics, (CYTK)

December 8, 2017 - By Clifton Ray

Shelton Capital Management decreased Jpmorgan Chase & Co (JPM) stake by 24.12% reported in 2017Q2 SEC filing. Shelton Capital Management sold 43,309 shares as Jpmorgan Chase & Co (JPM)’s stock declined 6.04%. The Shelton Capital Management holds 136,275 shares with $12.46 million value, down from 179,584 last quarter. Jpmorgan Chase & Co now has $362.95 billion valuation. The stock decreased 0.30% or $0.31 during the last trading session, reaching $104.62. About 13.37M shares traded or 6.63% up from the average. JPMorgan Chase & Co. (NYSE:JPM) has risen 33.74% since December 8, 2016 and is uptrending. It has outperformed by 17.04% the S&P500.

Among 12 analysts covering Cytokinetics (NASDAQ:CYTK), 11 have Buy rating, 0 Sell and 1 Hold. Therefore 92% are positive. Cytokinetics has $2600 highest and $13.0 lowest target. $20.17’s average target is 149.01% above currents $8.1 stock price. Cytokinetics had 21 analyst reports since July 24, 2015 according to SRatingsIntel. On Monday, November 9 the stock rating was maintained by Roth Capital with “Buy”. The rating was maintained by H.C. Wainwright with “Buy” on Thursday, August 3. As per Wednesday, November 22, the company rating was downgraded by Cantor Fitzgerald. Morgan Stanley maintained it with “Buy” rating and $17.0 target in Wednesday, November 22 report. The stock has “Buy” rating by Needham on Wednesday, July 27. The stock has “Buy” rating by Needham on Friday, September 15. The stock of Cytokinetics, Incorporated (NASDAQ:CYTK) earned “Market Outperform” rating by JMP Securities on Wednesday, March 9. The rating was maintained by Piper Jaffray on Tuesday, October 10 with “Buy”. MLV maintained Cytokinetics, Incorporated (NASDAQ:CYTK) on Friday, July 24 with “Buy” rating. Morgan Stanley maintained the shares of CYTK in report on Friday, October 6 with “Overweight” rating. See Cytokinetics, Incorporated (NASDAQ:CYTK) latest ratings:

22/11/2017 Broker: Morgan Stanley Rating: Buy New Target: $17.0 Maintain
21/11/2017 Broker: Piper Jaffray Rating: Buy New Target: $18.0 Maintain
22/11/2017 Broker: Cantor Fitzgerald Old Rating: Overweight New Rating: Neutral Downgrade
21/11/2017 Broker: JMP Securities Rating: Buy New Target: $13.0
27/10/2017 Broker: Needham Rating: Buy New Target: $22.0 Maintain
27/10/2017 Broker: H.C. Wainwright Rating: Buy New Target: $26.0 Maintain
10/10/2017 Broker: Piper Jaffray Rating: Buy New Target: $24.0 Maintain
06/10/2017 Broker: Seaport Global Rating: Buy New Target: $24 Initiates Coverage On
06/10/2017 Broker: Morgan Stanley Rating: Overweight Old Target: $24 New Target: $25 Maintain
18/09/2017 Broker: Cantor Fitzgerald Rating: Buy New Target: $21.0

Analysts await JPMorgan Chase & Co. (NYSE:JPM) to report earnings on January, 12. They expect $1.71 earnings per share, 0.00% or $0.00 from last year’s $1.71 per share. JPM’s profit will be $5.93 billion for 15.30 P/E if the $1.71 EPS becomes a reality. After $1.76 actual earnings per share reported by JPMorgan Chase & Co. for the previous quarter, Wall Street now forecasts -2.84% negative EPS growth.

Shelton Capital Management increased Du Pont E I De Nemours & Co (NYSE:DD) stake by 3,857 shares to 43,210 valued at $3.49 million in 2017Q2. It also upped Baidu Inc (NASDAQ:BIDU) stake by 1,948 shares and now owns 20,769 shares. Morgan Stanley (NYSE:MS) was raised too.

Among 32 analysts covering JPMorgan Chase & Co (NYSE:JPM), 17 have Buy rating, 2 Sell and 13 Hold. Therefore 53% are positive. JPMorgan Chase & Co had 88 analyst reports since July 21, 2015 according to SRatingsIntel. On Friday, October 13 the stock rating was maintained by BMO Capital Markets with “Market Perform”. The rating was maintained by Nomura with “Neutral” on Friday, October 13. The stock has “Neutral” rating by Robert W. Baird on Wednesday, November 9. The rating was upgraded by BMO Capital Markets on Wednesday, September 16 to “Outperform”. The stock has “Mkt Perform” rating by Keefe Bruyette & Woods on Tuesday, January 17. RBC Capital Markets maintained the stock with “Buy” rating in Monday, July 17 report. The rating was maintained by Argus Research with “Buy” on Wednesday, October 14. The firm has “Neutral” rating given on Monday, October 17 by Buckingham Research. Jefferies maintained JPMorgan Chase & Co. (NYSE:JPM) on Monday, October 10 with “Buy” rating. The firm earned “Neutral” rating on Friday, September 9 by Macquarie Research.

Investors sentiment increased to 1.19 in Q2 2017. Its up 0.32, from 0.87 in 2017Q1. It improved, as 56 investors sold JPM shares while 678 reduced holdings. 146 funds opened positions while 731 raised stakes. 2.69 billion shares or 4.21% more from 2.58 billion shares in 2017Q1 were reported. Retirement Of Alabama invested 1.37% of its portfolio in JPMorgan Chase & Co. (NYSE:JPM). Teacher Retirement Of Texas has invested 1.52% of its portfolio in JPMorgan Chase & Co. (NYSE:JPM). Moreover, Aperio Group Limited Liability Company has 0.99% invested in JPMorgan Chase & Co. (NYSE:JPM). Franklin Street Advisors Nc reported 149,101 shares. Financial Advisers Limited Liability Company invested in 674,049 shares. Buckingham Cap Mngmt Inc accumulated 1.82% or 86,397 shares. Meiji Yasuda Life reported 99,230 shares. Everett Harris Ca holds 0.05% or 15,997 shares. 225,427 are owned by Palisade Nj. Sigma Inv Counselors, a Michigan-based fund reported 67,478 shares. Amica Mutual reported 279,120 shares. Smith Asset Mngmt Group LP owns 290,546 shares. Channing Mngmt Limited holds 104,994 shares. Swift Run Management Limited Company has invested 0.13% in JPMorgan Chase & Co. (NYSE:JPM). Northern reported 48.97 million shares.

The stock increased 3.85% or $0.3 during the last trading session, reaching $8.1. About 543,142 shares traded. Cytokinetics, Incorporated (NASDAQ:CYTK) has risen 88.33% since December 8, 2016 and is uptrending. It has outperformed by 71.63% the S&P500.

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company has market cap of $436.47 million. The firm is developing small molecule drug candidates primarily engineered to increase muscle function and contractility. It currently has negative earnings. The Company’s lead drug candidate is Tirasemtiv, a fast skeletal troponin activator, which is in Phase III clinical trial in patients with amyotrophic lateral sclerosis.

Investors sentiment increased to 2.94 in Q2 2017. Its up 1.33, from 1.61 in 2017Q1. It improved, as 14 investors sold Cytokinetics, Incorporated shares while 17 reduced holdings. 44 funds opened positions while 47 raised stakes. 37.79 million shares or 34.95% more from 28.00 million shares in 2017Q1 were reported. Clarivest Asset Management Limited Liability Com accumulated 0.03% or 89,116 shares. Dimensional Fund Advsrs L P has invested 0% in Cytokinetics, Incorporated (NASDAQ:CYTK). Ameriprise Fincl stated it has 0% of its portfolio in Cytokinetics, Incorporated (NASDAQ:CYTK). Ameritas Invest Ptnrs stated it has 0% of its portfolio in Cytokinetics, Incorporated (NASDAQ:CYTK). 19,190 were accumulated by Voya Invest Mgmt Limited Liability. Bvf Il reported 1.99M shares. State Teachers Retirement invested in 0% or 19,192 shares. D E Shaw And has invested 0% in Cytokinetics, Incorporated (NASDAQ:CYTK). Barclays Public Limited Co, a United Kingdom-based fund reported 24,466 shares. Sterling Mngmt Limited has invested 0.01% in Cytokinetics, Incorporated (NASDAQ:CYTK). Moreover, Millennium Mgmt Lc has 0% invested in Cytokinetics, Incorporated (NASDAQ:CYTK) for 41,639 shares. New York-based Bnp Paribas Arbitrage Sa has invested 0% in Cytokinetics, Incorporated (NASDAQ:CYTK). Moreover, Wasatch Advsr has 0.13% invested in Cytokinetics, Incorporated (NASDAQ:CYTK). Legal & General Public Limited Liability Company stated it has 0% of its portfolio in Cytokinetics, Incorporated (NASDAQ:CYTK). Northern Trust reported 467,312 shares.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter:


Twitter Auto Publish Powered By : XYZScripts.com